Table 2B. Correlation of GRP78 protein with clinical parameter.
| MGUS | NDMM | RRMM | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GRP78 levels (ng/mL) | GRP78 levels (ng/mL) | GRP78 levels (ng/mL) | |||||||
| Parameter | N (%) | median | [95%CI] | N (%) | median | [95%CI] | N (%) | median | [95%CI] |
| Patients | 29 (100) | 2.5 | 1.7-6.4 | 29 (100) | 3.1 | 1.8-7.3 | 15 (100) | 4.0 | 1.7-7.7 |
| Osteolytic bone lesions | 0 | 27 (93) | 2.7 | 1.8-7.4 | 15(100) | 4.0 | 1.7-7.8 | ||
| Cytogenetic standard risk | 1 (3) | 9 (31) | 2.3 | 1.7-16.5 | 4(26) | 2.8 | 1.2-5.4 | ||
| Cytogenetic high risk | 1 (3) | 15 (52) | 5.4 | 1.5-13.2 | 10(67) | 5.8 | 1.7-8.7 | ||
| Cytogenetic not avail. | 27(94) | 5 (17) | 1(7) | Not av. | |||||
| BMPCs < 10% BMPCs < 20% BMPCs 20 - < 50% BMPCs >= 50% BMPCs percentage not avail. |
29 (100) 0 0 0 0 |
2.5 | 1.7-6.4 | 0 7(24) 6 (21) 7 (24) 9 (31) |
4.2 3.4 2.3 |
1.8-19.4 1.0-63.0 1.5.-48.5 |
0 2 (14) 5 (33) 3 (20) 5 (33) |
5.1 4.0 1.5 |
1.6-8.7 1.8-6.8 1.2-10.5 |
| Therapy lines at samples collection | |||||||||
| 1st line therapy | 0 | 0 | 0 | ||||||
| 2nd line + 3rd line therapy | 0 | 0 | 8 (53) | 2.9 | 1.6-7.8 | ||||
| 4th and higher lines of therapy | 0 | 0 | 7 (47) | 5.4 | 1.5-21.5 | ||||
| BTZ based therapy at sample collection | 0 | 0 | 9 (60) | 4.0 | 1.6-7.7 | ||||
| IMiDs based therapy at sample collection | 0 | 0 | 6 (40) | 4.3 | 1.6-25.0 | ||||
Abbrevations: BMPCs, Bone marrow plasma cells; IMiD, Immunomodulatory drugs; BTZ, Bortezomib.